Inhalation Sciences wins place on prestigious EU-funded Life Science Investment Hotlist

  • 12 April, 2019
  • 11:59

Stockholm is a world-famous hotspot for game-changing, early-stage life science companies—but which really have the most commercial potential? Funded by the EU European Regional Development Fund, the Invest Stockholm group selects the region’s most commercially innovative companies—and has now chosen Inhalation Sciences (ISAB) for the list.

Business and science leaders from all over the globe flock to Stockholm and Uppsala to find solutions in the region’s thriving, entrepreneurial Life Sciences hub. Now Stockholm City’s Invest Stockholm group, funded by the EU, formally curate a list of the region’s Life Science companies that their analysts believe are the most innovative, disruptive and commercially high-potential.

On Wednesday 10 April ISAB CEO Lena Heffler attended a packed event celebrating the Life Science Investment Hotlist at Nasdaq North Headquarters in Stockholm. Nasdaq North posted about the event live in Times Square in New York.

 Speakers included Anette Nordvall from prestigious early-stage investment group STOAF (Stockholm Business Angels, Stockholms Affärsänglar), who mentioned ISAB as one of the high-potential companies STOAF invests in.

ISAB CEO Lena Heffler: “making the right investment at the right time, in a company with the right research, the right solutions and the right customer relations – nothing is more important for investors. With this Hotlist Invest Stockholm gives investors smart, insightful, reliable intelligence. We’re delighted to be selected!”